vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v22i4.2598vsp-3266Research ArticleИНФОРМАЦИЯ СОЮЗА ПЕДИАТРОВ РОССИИINFORMATION FROM THE UNION OF PEDIATRICIANS OF RUSSIAРезолюция независимого экспертного совета союза экспертов в сфере иммунопрофилактикиResolution of the Independent Expert Council of The Union of Experts in the Field of ImmunoprophylaxisРедакционнаястатьяEditorialArticle202325082023224352357Copyright © Редакционная с., 20232023Редакционная с.Editorial a.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/3266

Профилактика инфекционных заболеваний является одним из приоритетов в сфере охраны здоровья (Федеральный закон от 21 ноября 2011 г. № 323-ФЗ «Об основах охраны здоровья граждан в Российской Федерации» (действующая редакция, 2016 г.).

иммунопрофилактикаReferencesПароксизмальная ночная гемоглобинурия: клинические рекомендации. — Минздрав России; 2021. Доступно по: https://cr.minzdrav.gov.ru/schema/695_1. Ссылка активна на 10.08.2023.Paroksizmal’naya nochnaya gemoglobinuriya: Clinical guidelines. Ministry of Health of Russia; 2021. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/schema/695_1. Ссылка активна на 10.08.2023.Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253– 1258. doi: https://doi.org/10.1056/NEJM199511093331904Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253–1258. doi: https://doi.org/10.1056/NEJM199511093331904Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and rognostic factors. French Society of Haematology. Lancet. 1996;348(9027):573–577. doi: https://doi.org/10.1016/S0140-6736(95)12360-1Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and rognostic factors. French Society of Haematology. Lancet. 1996;348(9027):573–577. doi: https://doi.org/10.1016/S0140-6736(95)12360-1Kelly R, Richards S, Hillmen P, Hill A. The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther Clin Risk Manag. 2009;5:911–921. doi: https://doi.org/10.2147/TCRM.S3334Kelly R, Richards S, Hillmen P, Hill A. The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther Clin Risk Manag. 2009;5:911–921. doi: https://doi.org/10.2147/TCRM.S3334McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011;71(17):2327–2345. doi: https://doi.org/10.2165/11208300-000000000-00000McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011;71(17):2327–2345. doi: https://doi.org/10.2165/11208300-000000000-00000Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123– 4128. doi: https://doi.org/10.1182/blood-2007-06-095646Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123– 4128. doi: https://doi.org/10.1182/blood-2007-06-095646Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137(3):181–192. doi: https://doi.org/10.1111/j.1365-2141.2007.06554.xHill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137(3):181–192. doi: https://doi.org/10.1111/j.1365-2141.2007.06554.xИнструкция по применению препаратов экулизумаб и равулизумаб.Instructions for use of eculizumab and ravulizumab. (In Russ).Инструкция по применению препарата пэгцетакоплан.Instructions for use of the drug pegcetacoplan. (In Russ).Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1–41. doi: https://doi.org/10.15585/mmwr.rr6909a1externaliconMbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1–41. doi: https://doi.org/10.15585/mmwr.rr6909a1externaliconImmunisation of individuals with underlying medical conditions: the green book, chapter 7: Guidance. 2013. Available online: https://https://www.gov.uk/government/publications/immunisation-of-individuals-with-underlying-medical-conditions-the-green-book-chapter-7. Accessed on August 10, 2023.Immunisation of individuals with underlying medical conditions: the green book, chapter 7: Guidance. 2013. Available online: https://https://www.gov.uk/government/publications/immunisation-of-individuals-with-underlying-medical-conditions-the-green-book-chapter-7. Accessed on August 10, 2023.Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86(47):521–540.Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86(47):521–540.Менингококковая инфекция и гнойные бактериальные менингиты в Российской Федерации 2021 г.: информационно-аналитический обзор. — ЦНИИ эпидемиологии Роспотребнадзора РФ; 2022.Meningokokkovaya infektsiya i gnoinye bakterial’nye meningity v Rossiiskoi Federatsii 2021 g.: Informational and analytical review. Central Research Institute of Epidemiology of Rospotrebnadzor of the Russian Federation; 2022. (In Russ).О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2022 году: государственный доклад. — М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека; 2023. — 368 с.O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiiskoi Federatsii v 2022 godu: State report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Welfare; 2023. 368 p. (In Russ).Girmenia C, Barcellini W, Bianchi P, et al. Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs. Blood Rev. 2023;58:101013. doi: https://doi.org/10.1016/j.blre.2022.101013Girmenia C, Barcellini W, Bianchi P, et al. Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs. Blood Rev. 2023;58:101013. doi: https://doi.org/10.1016/j.blre.2022.101013WHO. WHO position paper on Haemophilus influenzae type b conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record). Wkly Epidemiol Rec. 2006;81(47):445–452.WHO. WHO position paper on Haemophilus influenzae type b conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record). Wkly Epidemiol Rec. 2006;81(47):445–452.

The authors declare that there are no conflicts of interest present.